Background Recent advances in understanding the links between amyloid‐beta (Aβ) and
specific tau isoforms in brain, cerebrospinal fluid (CSF), and blood indicate that a cascade of …

Background Recent advances in the development of novel Alzheimer's disease (AD)
measures of amyloid, tau, and neurodegeneration in cerebrospinal fluid (CSF) and blood …

Background Especially because disease‐modifying treatments (DMTs) for Alzheimer
disease (AD) are likely to become more available soon, highly accurate AD blood tests for …

Background We aimed to investigate the tau biomarker discrepancies of Alzheimer's
disease (AD) using plasma tau phosphorylated at threonine 181 (p-tau181), cerebrospinal …

Plasma phospho-tau (p-tau) species have emerged as the most promising blood-based
biomarkers of Alzheimer's disease. Here, we performed a head-to-head comparison of p …

Background Alzheimer's disease (AD) is a multifactorial disease, with ongoing amyloid and
tau accumulation, axonal damage and astrocytosis. Blood‐based biomarkers reflecting …

INTRODUCTION To examine the extent to which positron emission tomography (PET)‐,
cerebrospinal fluid (CSF)‐, and plasma‐related amyloid‐β/tau/neurodegeneration (A/T/N) …

Abstract Introduction Blood‐based Alzheimer's disease (AD) biomarkers provide
opportunities for community studies and across ethnic groups. We investigated blood …

Cerebrospinal fluid (CSF) tau and phosphorylated tau (ptau) are definite biomarkers of
Alzheimer's disease (AD). After discovery of presence and increased levels tau in CSF from …

INTRODUCTION Plasma biomarkers are promising tools for Alzheimer's disease (AD)
diagnosis, but comparisons with more established biomarkers are needed. METHODS We …